Brief: CASI Pharmaceuticals, Receives Nasdaq Deficiency Notice
03/01/2022 12:21
Jan 3 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE
Source text for Eikon: ID:nPn70pb3na
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary